Listen Live

Binghamton University Enters Research Agreement with Sunshine Biopharma

Sunshine Biopharma and Binghamton University have entered into a research and development agreement to conduct clinical studies and Phase 1 trials on a new drug to treat breast and prostate cancer.
The drug inhibits an enzyme found in drug resistant forms of breast cancer as well as in other types of aggressive cancer.
Early data indicates the compound is three times more effective in arresting cancer cell growth than the current treatment.
The agreement is for three years.
Dr. Susannah Gal will lead the work for Binghamton University. Dr Gal is a cancer survivor herself.

Leave a Reply

Your email address will not be published. Required fields are marked *